Ministry of Health Convenes the First Meeting of the Egyptian Vaccine Manufacturers Alliance (EVMA) Committee Following Governance Decree

Cairo, 8^th March 2026.

In a strategic step to strengthen governance of Egypt’s vaccine manufacturing sector, the Ministry of Health and Population convened the first meeting of the Egyptian Vaccine Manufacturers Alliance (EVMA) Committee, chaired by Dr. Amr Kandil, Deputy Minister of Health and Population. The meeting was held in implementation of Ministerial Decree No. 449 of 2025, which formally established the committee.

The establishment of the committee represents an important institutional milestone aimed at aligning efforts between government entities and the private sector to advance the localization of vaccine manufacturing and strengthen Egypt’s capacity to meet domestic demand while contributing to regional health security.

The meeting brought together senior representatives from the Unified Procurement Authority (UPA) and the Egyptian Drug Authority (EDA), alongside officials from the Ministries of Finance, Planning, and Investment, as well as leading national and international vaccine manufacturers. This multi-stakeholder participation reflects a coordinated framework bringing together regulatory, procurement, financial, and industrial actors to support the development of Egypt’s vaccine manufacturing ecosystem.

During the meeting, Dr. Amr Kandil reviewed two proposals submitted by international companies for the localization of seasonal influenza vaccine manufacturing in Egypt, noting that the proposals were discussed in light of the state’s strategic vision to identify the most suitable model that would strengthen national manufacturing capacity while supporting export opportunities.

For his part, Dr. Hesham Badr, Vice President of the Unified Procurement Authority, emphasized that Egypt possesses well-equipped manufacturing facilities and strong production capabilities, positioning the country to play a leading role in vaccine manufacturing at the African level.

Dr. Tamer El-Husseiny, Vice President of the Egyptian Drug Authority, also reaffirmed the authority’s commitment to providing the necessary regulatory and technical support to facilitate manufacturing and enable companies to meet international standards and expand export opportunities.

The committee further discussed technology transfer mechanisms and proposed implementation steps supported by defined timelines aligned with international standards. The discussions concluded with the development of a roadmap outlining priority actions for the upcoming phase.

As the first meeting of the committee following the issuance of the governance decree, the meeting marks an important step toward strengthening institutional coordination across Egypt’s vaccine manufacturing ecosystem, supporting the implementation of the national strategy for vaccine manufacturing localization and advancing Egypt’s ambition to become a regional hub for vaccine manufacturing and export in the Middle East and Africa.